Haleon has achieved significant operational leverage, driving operating margins to 22.7% in 2025Q4 despite a challenging revenue environment that saw a 0.4% decline in the same period.
| Sales/Revenue | 10.79B | 11.23B | 11.3B | 10.86B | 9.54B | 9.89B | 8.48B |
| Revenue Growth % | -3.96% | -0.61% | 4.09% | 13.76% | -3.51% | 16.65% | - |
| Cost of Goods Sold | 3.8B | 4.29B | 4.34B | 4.28B | 3.6B | 3.98B | 3.68B |
| COGS % of Revenue | 35.23% | 38.15% | 38.41% | 39.43% | 37.66% | 40.25% | 43.37% |
| Gross Profit | 6.99B | 6.95B | 6.96B | 6.58B | 5.95B | 5.91B | 4.8B |
| Gross Margin % | 64.77% | 61.85% | 61.59% | 60.57% | 62.34% | 59.75% | 56.63% |
| Gross Profit Growth % | 0.57% | -0.19% | 5.84% | 10.54% | 0.68% | 23.07% | - |
| Operating Expenses | 4.57B | 4.74B | 4.96B | 4.75B | 4.31B | 4.31B | 3.9B |
| OpEx % of Revenue | 42.33% | 42.21% | 43.93% | 43.77% | 45.18% | 43.59% | 46.05% |
| Selling, General & Admin | 4.26B | 4.33B | 4.29B | 4.04B | 3.79B | 4.22B | 3.6B |
| SG&A % of Revenue | 39.47% | 38.57% | 37.94% | 37.18% | 39.74% | 42.66% | 42.41% |
| Research & Development | 308.1M | 298M | 311M | 300M | 257M | 304M | 292M |
| R&D % of Revenue | 2.86% | 2.65% | 2.75% | 2.76% | 2.69% | 3.07% | 3.44% |
| Other Operating Expenses | 0 | 111M | 366M | 415M | 262M | -212M | 17M |
| Operating Income | 2.42B | 2.21B | 2B | 1.82B | 1.64B | 1.6B | 897M |
| Operating Margin % | 22.44% | 19.64% | 17.66% | 16.81% | 17.16% | 16.15% | 10.58% |
| Operating Income Growth % | 9.74% | 10.52% | 9.37% | 11.42% | 2.5% | 78.15% | - |
| EBITDA | 2.77B | 2.4B | 2.31B | 2.11B | 1.91B | 1.9B | 1.16B |
| EBITDA Margin % | 25.7% | 21.38% | 20.39% | 19.45% | 19.97% | 19.24% | 13.64% |
| EBITDA Growth % | 15.44% | 4.21% | 9.14% | 10.81% | 0.16% | 64.48% | - |
| D&A (Non-Cash Add-back) | 352.11M | 196M | 309M | 287M | 268M | 305M | 260M |
| EBIT | 2.42B | 2.32B | 2.04B | 1.9B | 1.94B | 1.61B | 912M |
| Net Interest Income | -256.26M | -339M | -400M | -278.38M | -3M | -7.69M | -2.55M |
| Interest Income | 76.29M | 55M | 14M | 68.98M | 13M | 17.95M | 25.51M |
| Interest Expense | 332.55M | 394M | 414M | 347.36M | 16M | 25.65M | 28.07M |
| Other Income/Expense | -315.92M | -296M | -368M | -207M | -2M | -7M | -11M |
| Pretax Income | 2.1B | 1.91B | 1.63B | 1.62B | 1.64B | 1.59B | 886M |
| Pretax Margin % | 19.51% | 17% | 14.4% | 14.9% | 17.14% | 16.08% | 10.45% |
| Income Tax | 461.66M | 435M | 517M | 499M | 197M | 410M | 199M |
| Effective Tax Rate % | 21.93% | 22.77% | 31.76% | 30.84% | 12.04% | 25.77% | 22.46% |
| Net Income | 1.63B | 1.44B | 1.05B | 1.06B | 1.39B | 1.15B | 655M |
| Net Margin % | 15.11% | 12.84% | 9.28% | 9.76% | 14.56% | 11.58% | 7.72% |
| Net Income Growth % | 13.07% | 37.46% | -1.04% | -23.74% | 21.4% | 74.81% | - |
| Net Income (Continuing) | 1.64B | 1.48B | 1.11B | 1.12B | 1.44B | 1.18B | 687M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 58.9M | 58M | 123M | 126M | 125M | 111M | 91M |
| EPS (Diluted) | 0.36 | 0.32 | 0.24 | 0.24 | 0.30 | 0.24 | 0.14 |
| EPS Growth % | 12.5% | 33.33% | 0% | -20% | 25% | 71.43% | - |
| EPS (Basic) | 0.36 | 0.32 | 0.24 | 0.24 | 0.30 | 0.24 | 0.14 |
| Diluted Shares Outstanding | 4.51B | 4.59B | 4.63B | 4.62B | 4.62B | 4.62B | 4.62B |
| Basic Shares Outstanding | 4.48B | 4.57B | 4.63B | 4.62B | 4.62B | 4.62B | 4.62B |
| Dividend Payout Ratio | 36.71% | 39.53% | 36.99% | 253.02% | 82.59% | 207.07% | 175.88% |
Technical share overhang pressure
As reported in recent financial statements, Haleon's revenue growth has decelerated to a negative 0.4% in 2025Q4, reflecting a challenging environment where the company's strategic divestment of non-core assets appears to be offsetting organic volume gains across its primary oral health and pain relief categories.
The persistent negative growth trend suggests that the company is prioritizing margin quality over top-line expansion as it sheds lower-margin legacy products. Investors should monitor whether this contraction is a temporary byproduct of portfolio pruning or an indication of weakening demand for its core power brands in key markets.
Based on reported figures, Haleon has successfully expanded its gross margin to 65.0% in 2025Q4, demonstrating a resilient pricing power that allows the firm to maintain premium positioning despite the broader inflationary pressures impacting the consumer healthcare sector's input costs for raw materials and packaging.
This margin profile appears superior to peers like Kenvue and Procter & Gamble, suggesting that the clinical endorsement model for brands like Sensodyne provides a significant buffer against private label competition. The ability to sustain these levels implies that the company's focus on high-margin power brands is effectively insulating the bottom line from commodity volatility.
According to recent SEC filings, Haleon's operating margin reached 22.7% in 2025Q4, indicating that management is successfully stripping out stranded costs inherited from its former parent companies and achieving greater operational efficiency as a standalone entity compared to the 14.7% margin observed in 2021Q2.
The scaling of operating income relative to gross profit suggests that the company is gaining control over its SG&A overhead, which has remained relatively flat even as the business model matures. This trend warrants further investigation to determine if the current efficiency gains are sustainable or if they rely on temporary reductions in marketing spend.
As indicated by the income statement data, net income has grown to $855.7 million in 2025Q4, with EPS rising 18.8% year-over-year, suggesting that the company's earnings quality is improving as the impact of one-time separation costs and stock-based compensation volatility begins to normalize.
The reduction in stock-based compensation from $102 million in 2024Q4 to zero in 2025Q4 significantly enhances the quality of reported earnings, reducing the dilution risk for shareholders. However, investors should remain cautious regarding the potential for future non-operating charges related to legacy litigation, which could periodically obscure the underlying operational performance.
While Haleon maintains strong margins, the persistent negative revenue growth trend, as shown in recent filings, raises concerns that the company's reliance on premium pricing may eventually trigger a consumer trade-down to private label alternatives in a more price-sensitive global macroeconomic environment.
Short-sellers may focus on the risk that the 'professional recommendation' moat is not as impenetrable as management suggests, particularly if retail gatekeepers prioritize their own house brands. The lack of top-line growth suggests that the company may be reaching a ceiling in its ability to pass through price increases without sacrificing volume.
Quick answers to the most common questions about buying HLN stock.
For fiscal year 2025, Haleon plc (HLN) reported total revenue of $10.79B. This represents a 27.2% increase compared to $8.48B in 2019.
Haleon plc (HLN) is profitable, generating $1.63B in net income for the fiscal year ending 2025 with a net profit margin of 15.1%.
Haleon plc (HLN) reported an operating income of $2.42B, resulting in an operating profit margin of 22.4%. This margin reflects the operational efficiency of the business before interest and taxes.
Haleon plc (HLN) generated $6.99B in gross profit for the year, representing a gross profit margin of 64.8%. This demonstrates the company's core pricing power and production efficiency.